ProMIS Neurosciences
- Country
- 🇨🇦Canada
- Ownership
- -
- Employees
- 6
- Market Cap
- -
- Introduction
ProMIS Neurosciences Inc is focused on the discovery and development of precision medicine solutions for early detection and effective treatment of neurodegenerative diseases, including Alzheimer's disease, amyotrophic lateral sclerosis, and multiple system atrophy. The company also plans to investigate additional synucleionapathies, including Parkinson's disease, and dementia with Lewy bodies. It operates in Canada.
Clinical Trials
2
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (2 trials with phase data)• Click on a phase to view related trials
PMN310 in Patients With Early Alzheimer's Disease (PRECISE-AD)
- First Posted Date
- 2024-12-27
- Last Posted Date
- 2025-06-22
- Lead Sponsor
- ProMis Neurosciences, Inc
- Target Recruit Count
- 128
- Registration Number
- NCT06750432
- Locations
- 🇺🇸
Irvine Center for Clinical Research, Irvine, California, United States
🇺🇸Healthy Brain Research, Long Beach, California, United States
🇺🇸JEM Research Institute, Atlantis, Florida, United States
A Phase 1a Study of PMN310 In Healthy Volunteers
- First Posted Date
- 2023-10-27
- Last Posted Date
- 2024-02-20
- Lead Sponsor
- ProMis Neurosciences, Inc
- Target Recruit Count
- 40
- Registration Number
- NCT06105528
- Locations
- 🇺🇸
Clinical Pharmacology of Miami, LLC, Miami, Florida, United States
🇺🇸Ohio Clinical Trials, Columbus, Ohio, United States
News
ProMIS Neurosciences to Present at Guggenheim Securities SMID Cap Biotech Conference
ProMIS Neurosciences will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on February 5, 2025.
Walden Biosciences Advances Kidney Disease Therapies with WAL0921 and WAL0623
Walden Biosciences has fully enrolled the second cohort in its Phase 2 basket study of WAL0921 for chronic kidney disease, targeting diabetic nephropathy.
ProMIS Neurosciences Initiates Phase 1b Trial of PMN310 for Alzheimer's Disease
ProMIS Neurosciences has begun a Phase 1b clinical trial (PRECISE-AD) to evaluate PMN310 for Alzheimer's, targeting toxic amyloid-beta oligomers.
ProMIS Neurosciences' PMN310 Shows Promise in Phase 1a Alzheimer's Trial
PMN310, a monoclonal antibody targeting toxic amyloid beta oligomers, was well-tolerated in a Phase 1a trial with healthy volunteers.
ProMIS Neurosciences' PMN310 Shows Promise in Phase 1a Alzheimer's Trial
ProMIS Neurosciences presented Phase 1a clinical trial data for PMN310, indicating it was generally well-tolerated in healthy volunteers.